Regeneron touts possible 'best-in-class' myeloma bispecific, but adverse events climb to 100%

All patients reported at least one adverse event and 14 deaths occurred "due to treatment-emergent" adverse events in the early-stage trial. Regeneron posted the results Thursday ahead of this weekend's American Society of Hematology's annual meeting.